Tag Archive for: oncology

Poolbeg Pharma plc – POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza

/in

Patent decision strengthens Poolbeg’s intellectual property portfolio 30 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces it has received notification of the official decision to grant Poolbeg’s Immunomodulator II patent in South Africa, providing protection for POLB 001 for the prevention of hypercytokinaemia and […]

Read more

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

/in

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025 Oslo, Norway, 18 June 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of […]

Read more

Poolbeg Pharma plc – Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS

/in

Major milestone will provide IP protection in key European markets, strengthening global patent portfolio 16 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced […]

Read more

Poolbeg Pharma plc – Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress

/in

Posters highlight POLB 001’s potential in CRS prevention and ability to enhance AML treatment in elderly patients, potentially expanding into a new indication  ·    First poster shows that POLB 001 decreased key CRS-associated cytokines and did not impair bispecific antibody-induced tumour cell death in a series of preclinical investigations ·    Second poster demonstrates the potential for POLB […]

Read more

Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial

/in

Major operational milestone achieved with interim data on track for summer 2026 11 June 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred. This follows the successful completion of […]

Read more
© Optimum Strategic Communications.